Halozyme Therapeutics (HALO) FCF Margin (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of FCF Margin data on file, last reported at 46.81% in Q1 2026.

• FCF Margin for Q1 2026 came in at 46.81%, down 1123.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 44.63% (down 94.0% YoY), and the FY2025 annual result was 46.59%, up 46.0% from the prior year.
• FCF Margin fell to 46.81% in Q1 2026 per HALO's latest filing, from 49.51% in the prior quarter.
• Over five years, FCF Margin peaked at 65.3% in Q1 2024 and troughed at 22.12% in Q2 2024.
• A 5-year average of 43.74% and a median of 44.14% in 2022 frame the typical range for FCF Margin.
• The sharpest annual moves came in 2022 and 2023: FCF Margin plunged 7183 bps in 2022, then surged 2851 bps in 2023.
• A 5-year view of FCF Margin shows it stood at 44.14% in 2022, then declined by 14 bps to 38.08% in 2023, then surged by 55 bps to 58.86% in 2024, then decreased by 16 bps to 49.51% in 2025, then declined by 5 bps to 46.81% in 2026.
• Business Quant data shows HALO's FCF Margin at 46.81% in Q1 2026, 49.51% in Q4 2025, and 49.56% in Q3 2025.